Study Leads to Practice-changing Implications for AML Patients
Dr. Ed Copelan
Dr. Belinda Avalos
Edward Copelan, MD, and Belinda Avalos, MD, chair and vice-chair of the Hematologic Oncology and Blood Disorders program at Levine Cancer Institute, recently led a large international study with practice-changing implications for acute myeloid leukemia (AML) patients. The study was selected as the plenary article for publication in Blood, which is the nation’s leading hematology journal.
The study, from the Center for International Blood And Marrow Transplant Research, analyzed more than 1,200 patients who underwent transplantation from siblings or unrelated donors to compare the effectiveness of BuCy (a combination of the chemotherapy drugs cyclophosphamide and buslufan) and CyTBI (cyclophosphamide and total body irradiation) for the treatment of AML.The findings significantly favor the use of BuCy, due to improved transplant-related mortality and overall survival rates, as well as ease of administration.
Under Dr. Copelan and Dr. Avalos’ leadership, the Institute is dramatically expanding its hematology-oncology program including the development of a translational research lab devoted to testing new therapies and treatments for blood cancer patients and the construction of a new state-of-the-art hematologic malignancies unit, where bone marrow transplants will be performed.